X

Trial Profile

A 50-Week Open-Label, Flexible-Dose Trial of Asenapine Extension Treatment to P06107 in Pediatric Subjects With Acute Manic or Mixed Episodes Associated With Bipolar I Disorder

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 05 May 2022

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Asenapine (Primary)
Indications Bipolar I disorders
Focus Adverse reactions
Acronyms ADDRESS-98
Sponsors Merck Sharp & Dohme; Organon

Most Recent Events

08 Oct 2016 New trial record
08 Jul 2013 Planned end date changed from Aug 2014 to Sep 2014
19 Mar 2012 Planned end date changed from Sep 2013 to Aug 2013

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com